Companies in #Cancer Vaccines
Found 3 companies operating in this sector.
Anixa Biosciences is a clinical-stage biotechnology company developing vaccines and therapeutics for cancer and infectious disease. Lead programs include a breast cancer vaccine licensed from Cleveland Clinic and an ovarian cancer vaccine in collaboration with Moffitt Cancer Center.
Elicio Therapeutics is a clinical-stage biotechnology company developing potent immunotherapies using its proprietary Amphiphile vaccine platform, which delivers immunogens directly to the lymph nodes to amplify immune responses against cancer. Its lead program ELI-002 is a KRAS-targeted cancer vaccine being studied in mKRAS-positive pancreatic ductal adenocarcinoma and other solid tumors. In June 2026 the Phase 2 AMPLIFY-201 trial missed its primary endpoint, sending shares down sharply, though the company said it will still advance to a Phase 3 study based on a subpopulation signal.
Scancell Holdings plc (LSE: SCLP) is a clinical-stage immuno-oncology company developing novel cancer vaccines and T-cell receptor (TCR) therapies. Its lead asset, iSCIB1+, is a DNA-based cancer vaccine entering second-half 2026 clinical trials. Plans Nasdaq listing via reverse merger with Neuphoria.